89 related articles for article (PubMed ID: 24139969)
1. Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy.
Hatakeyama Y; Kobayashi K; Nagano T; Tamura D; Yamamoto M; Tachihara M; Kotani Y; Nishimura Y
Cancer Lett; 2014 Feb; 343(1):74-9. PubMed ID: 24139969
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Li T; Ling YH; Goldman ID; Perez-Soler R
Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
6. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
Molina JR; Adjei AA
Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
Kano Y; Tanaka M; Akutsu M; Mori K; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1129-37. PubMed ID: 19306094
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
Okamoto I; Takeda K; Daga H; Miyazaki M; Yonesaka K; Kiyota H; Tsurutani J; Ueda S; Ichikawa Y; Takeda M; Sekiguchi R; Tominaga K; Enatsu S; Nambu Y; Nakagawa K
Lung Cancer; 2010 Nov; 70(2):168-73. PubMed ID: 20236726
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
12. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection.
Araujo AM
J Clin Oncol; 2010 Mar; 28(8):e131; author reply e132. PubMed ID: 20100954
[No Abstract] [Full Text] [Related]
18. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
19. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.
Brade A; Bezjak A; MacRae R; Laurie S; Sun A; Cho J; Leighl N; Pearson S; Southwood B; Wang L; McGill S; Iscoe N; Shepherd FA
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1395-401. PubMed ID: 20605367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
